Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Lestini

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Pharmaceutical Research|July 1, 2015
Influence of the Size of Cohorts in Adaptive Design for Nonlinear Mixed Effects Models: An Evaluation by Simulation for a Pharmacokinetic and Pharmacodynamic Model for a Biomarker in OncologyGiulia Lestini, Cyrielle Dumont, France Mentré
Journal of Pharmacokinetics and Pharmacodynamics|January 12, 2026
Concentration response analyses for QT data with several active compoundsGünter Heimann, Giulia Lestini, Jochen Zisowsky
The AAPS Journal|June 17, 2016
Optimal Design for Informative Protocols in Xenograft Tumor Growth Inhibition Experiments in MiceGiulia Lestini, France Mentré, Paolo Magni
Computer Methods and Programs in Biomedicine|February 12, 2018
PFIM 4.0, an extended R program for design evaluation and optimization in nonlinear mixed-effect modelsCyrielle Dumont, Giulia Lestini, Hervé Le Nagard, et al.
Clinical and Translational Science|May 18, 2024
First-in-human safety, tolerability, and pharmacokinetic results of DFV890, an oral low-molecular-weight NLRP3 inhibitorEwa Gatlik, Beata Mehes, Emilie Voltz, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 24, 2017
Model Description Language (MDL): A Standard for Modeling and SimulationMike K Smith, Stuart L Moodie, Roberto Bizzotto, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Pharmaceutical Research|July 1, 2015
Influence of the Size of Cohorts in Adaptive Design for Nonlinear Mixed Effects Models: An Evaluation by Simulation for a Pharmacokinetic and Pharmacodynamic Model for a Biomarker in OncologyGiulia Lestini, Cyrielle Dumont, France Mentré
Journal of Pharmacokinetics and Pharmacodynamics|January 12, 2026
Concentration response analyses for QT data with several active compoundsGünter Heimann, Giulia Lestini, Jochen Zisowsky
The AAPS Journal|June 17, 2016
Optimal Design for Informative Protocols in Xenograft Tumor Growth Inhibition Experiments in MiceGiulia Lestini, France Mentré, Paolo Magni
Computer Methods and Programs in Biomedicine|February 12, 2018
PFIM 4.0, an extended R program for design evaluation and optimization in nonlinear mixed-effect modelsCyrielle Dumont, Giulia Lestini, Hervé Le Nagard, et al.
Clinical and Translational Science|May 18, 2024
First-in-human safety, tolerability, and pharmacokinetic results of DFV890, an oral low-molecular-weight NLRP3 inhibitorEwa Gatlik, Beata Mehes, Emilie Voltz, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 24, 2017
Model Description Language (MDL): A Standard for Modeling and SimulationMike K Smith, Stuart L Moodie, Roberto Bizzotto, et al.
Pageof 1